Goserelin

證據等級: L5

預測適應症: 3 個

Goserelin: From Hormone-Sensitive Breast Cancer to Amenorrhea

One-Sentence Summary

Goserelin (Zoladex) is a GnRH agonist with established clinical use in hormone-sensitive breast cancer and endometriosis, acting by suppressing pituitary gonadotropin secretion and inducing ovarian estrogen deprivation. The TxGNN model predicts it may be effective for Amenorrhea (disease) — encompassing both therapeutic amenorrhea induction and chemotherapy-induced ovarian protection — with 7 clinical trials and 19 publications currently supporting this direction, achieving an L1 evidence level.

Quick Overview

Item	Content
Original Indication	Hormone-sensitive breast cancer; endometriosis (known clinical uses; no Italy/AIFA marketing authorization on record)
Predicted New Indication	Amenorrhea (disease)
TxGNN Prediction Score	99.99%
Evidence Level	L1
Italy Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not retrievable from the DrugBank query for this report. Based on well-established pharmacology, Goserelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH). Continuous administration paradoxically downregulates pituitary GnRH receptors through desensitisation, suppressing LH and FSH secretion, which in turn sharply reduces ovarian estrogen production in premenopausal women — directly inducing amenorrhea through a hormonal cascade.

This mechanistic pathway supports the TxGNN prediction from two clinically distinct angles. In the first, Goserelin deliberately induces therapeutic amenorrhea: suppressing the hormonal milieu is itself the treatment goal, as in hormone-sensitive breast cancer (reducing tumor-promoting estrogen), endometriosis (starving ectopic endometrial tissue), and uterine adenomyosis. In the second, pre-chemotherapy Goserelin administration temporarily drives ovarian follicles into a quiescent state, shielding them from cytotoxic damage — thereby preventing chemotherapy-induced amenorrhea and preserving fertility.

Both directions are mechanistically coherent and have been directly tested in large RCTs. The OPTION trial (n=400), IBCSG Trial VIII, and multiple supporting Phase 3 studies represent the strongest possible evidence base. The TxGNN model's top-ranked prediction for Goserelin precisely mirrors its validated pharmacodynamic fingerprint, making this one of the model's most mechanistically transparent predictions.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00427245	Phase 3	Completed	400	OPTION trial: large RCT testing goserelin vs no goserelin to prevent early menopause (chemotherapy-induced amenorrhea) in premenopausal women with stages I–III breast cancer
NCT00068601	Phase 3	Completed	257	Phase 3 RCT with ovarian failure (amenorrhea) as primary endpoint; evaluated whether goserelin prevents early menopause in HR-negative breast cancer patients receiving chemotherapy
NCT02483767	Phase 3	Completed	98	Prospective RCT directly assessing GnRH agonist (goserelin) for ovarian function preservation during chemotherapy in premenopausal breast cancer; sufficient data on amenorrhea outcomes
NCT01218581	Phase 2/3	Completed	32	RCT comparing aromatase inhibitors vs GnRH agonists in uterine adenomyosis; amenorrhea is a secondary outcome in fertility-preserving management
NCT02132390	Phase 3	Unknown	300	Adjuvant toremifene ± goserelin in premenopausal HR+ stages I–IIIA breast cancer; goserelin-induced amenorrhoea explicitly incorporated into study design
NCT03475758	Phase 2	Unknown	100	Goserelin for ovarian protection in premenopausal patients on cyclophosphamide-containing chemotherapy; menstruation outcome is the primary endpoint
NCT00488722	N/A	Unknown	N/A	Single-arm study of Zoladex + CEF neoadjuvant chemotherapy; explicitly notes goserelin's capacity to induce reversible amenorrhea equivalent to ovarian ablation

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28472240	2017	Meta-analysis / Systematic Review of RCTs	Annals of Oncology	OPTION trial final results: GnRH agonist co-administration significantly reduced chemotherapy-induced premature ovarian insufficiency (POI) and amenorrhea in early breast cancer
12488406	2002	RCT	Journal of Clinical Oncology	ZEBRA study: goserelin vs CMF chemotherapy as adjuvant therapy in premenopausal node-positive breast cancer; long-term amenorrhea and premature menopause directly compared
8513962	1993	RCT	Fertility and Sterility	Goserelin vs low-dose oral contraceptive for endometriosis-associated pelvic pain; amenorrhea induction is the primary therapeutic mechanism evaluated
14679153	2003	RCT	Journal of the National Cancer Institute	IBCSG Trial VIII: sequential chemotherapy + goserelin vs either alone for premenopausal node-negative breast cancer; ovarian suppression and amenorrhea as core treatment outcomes
17159194	2007	Secondary analysis of RCT	Journal of Clinical Oncology	IBCSG Trial VIII QoL analysis: differential impact of chemotherapy, goserelin, and their combination on amenorrhea, hot flashes, and quality of life by age group
25187267	2015	Prospective Cohort	Cancer Research and Treatment	Goserelin ovarian ablation improved survival in HR+ stages II/III breast cancer patients without chemotherapy-induced amenorrhea; highlights amenorrhea status as prognostic stratifier
12734855	2003	Review / Meta-analysis	British Journal of Surgery	Comprehensive review of ovarian ablation methods for adjuvant breast cancer treatment; GnRH agonists including goserelin assessed as reversible, effective amenorrhea-inducing strategy
12353820	2002	Review	Breast Cancer Research and Treatment	Overview of LHRH agonists in early breast cancer; goserelin's reversible ovarian ablation and amenorrhea induction highlighted as equivalent to CMF in hormone-sensitive disease
1533675	1992	Review	Journal of the Royal Army Medical Corps	Early review on therapeutic amenorrhea induction; goserelin identified as highly effective for controlled elimination of menstruation with fewer side effects than continuous oral contraceptives
10730389	1999	Clinical Study	Akusherstvo i Ginekologiia	GnRH agonist (Zoladex depot) used to manage severe uterine haemorrhage in adolescents with congenital aplastic/hypoplastic anaemia; amenorrhea induction stopped bleeding within 2–4 days

Cytotoxicity

Goserelin is used in the treatment of hormone-sensitive cancers (breast cancer, prostate cancer) and qualifies as an antineoplastic hormonal agent.

Item	Content
Cytotoxicity Classification	Hormonal / Endocrine therapy — GnRH agonist (not conventional cytotoxic chemotherapy)
Myelosuppression Risk	Low — mechanism is hormonal, not myelotoxic; bone marrow effects not expected
Emetogenicity Classification	Minimal — injection site reactions more common than nausea
Monitoring Items	Serum estradiol or testosterone (to confirm suppression), LH/FSH, bone mineral density (with use >6 months), liver function
Handling Protection	Standard pharmaceutical handling; cytotoxic drug handling precautions are not required

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction is mechanistically transparent — Goserelin's core pharmacodynamic action directly modulates amenorrhea — and is backed by multiple completed Phase 3 RCTs (including the 400-patient OPTION trial and IBCSG Trial VIII), placing this indication firmly at evidence level L1. The clinical goal must be clearly defined before proceeding, as Goserelin both induces and prevents amenorrhea depending on context.

To proceed, the following is needed:

Confirm clinical intent: therapeutic amenorrhea induction (e.g., adenomyosis, endometriosis) vs. chemotherapy-induced amenorrhea prevention (ovarian protection) — these are pharmacologically opposite applications requiring separate clinical pathways
Retrieve full MOA documentation from DrugBank to complete the mechanistic dossier
Verify Italy/AIFA registration status for Goserelin (marketed globally as Zoladex; current query returned 0 results, which may reflect a data gap rather than true non-approval)
Develop a long-term safety monitoring plan covering bone mineral density loss (hypo-estrogenic state) and cardiovascular effects with prolonged use
Assess fertility preservation and paediatric use cases separately, as these require dedicated clinical and ethical review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.